Clinical trial · Interventional
Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years
PETHEMA-LAM99:Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years
NCT00464217CI-TRIAL-00002960completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To reproduce or to improve the index of complete responses of protocol LMA-91 with a similar protocol, decreasing the dose of Idarubicin to try to reduce the deaths in induction
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloblastic Leukaemia | Acute Myeloid Leukemia | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ARA-C | Drug | Cytarabine | ALIAS |
| Idarubicin | Drug | Idarubicin | ALIAS |
| Leucomax | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Improve the complete response index in patients diagnosed of acute myeloblastic leukaemia over 65 years
Secondary outcomes (2)
- measure
- Evaluate the toxicity
- measure
- Evaluate the effect of haematopoietic growth factors
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Cytologic diagnosis of acute myeloblastic leukaemia (excluded M3) * Over 65 years Exclusion Criteria: * Previous diagnosis of other malignancy hematopoietic disorder or myelodysplastic syndrome * Previous treatment with antileucemic chemotherapy * Psychiatric disorder * Diagnosis of subtype FAB M3 * Creatinine \> 2.5 mg/dL * Bilirubin , Alkaline Phosphatase or transaminases three times upper the limit
References
Publications (1)
- DERIVEDMartinez-Lopez J, Fernandez-Redondo E, Garcia-Sanz R, Montalban MA, Martinez-Sanchez P, Pavia B, Mateos MV, Rosinol L, Martin M, Ayala R, Martinez R, Blanchard MJ, Alegre A, Besalduch J, Bargay J, Hernandez MT, Sarasquete ME, Sanchez-Godoy P, Fernandez M, Blade J, San Miguel JF, Lahuerta JJ; GEM (Grupo Espanol Multidisciplinar de Melanoma)/PETHEMA (Programa para el Estudio de la Terapeutica en Hemopatias Malignas) cooperative study group. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study. Br J Haematol. 2013 Dec;163(5):581-9. doi: 10.1111/bjh.12576. Epub 2013 Oct 3. PMID 24117042